According to Gram Research analysis of 2026 guidelines from the American Academy of Dermatology, five medications (adalimumab, bimekizumab, infliximab, secukinumab, and upadacitinib) have strong scientific evidence for treating hidradenitis suppurativa, a painful skin condition affecting 0.7 to 1.5 percent of people worldwide. The guidelines also strongly recommend regular pain assessment and management, along with conditional support for antibiotics, topical treatments, and lifestyle changes like smoking cessation.

Hidradenitis suppurativa is a painful skin condition affecting 1 in 100 people worldwide, causing serious discomfort and affecting daily life. According to Gram Research analysis, the American Academy of Dermatology and Hidradenitis Suppurativa Foundation released new guidelines in 2026 with 37 evidence-based treatment recommendations. The guidelines strongly support five specific medications (adalimumab, bimekizumab, infliximab, secukinumab, and others) and recommend regular pain assessment. Additional treatments like antibiotics, topical creams, and lifestyle changes like quitting smoking also show promise. These guidelines help doctors choose the best treatments based on solid scientific evidence.

Key Statistics

A 2026 systematic review by the American Academy of Dermatology and Hidradenitis Suppurativa Foundation identified five biologic medications with strong evidence for treating hidradenitis suppurativa: adalimumab, bimekizumab, infliximab, secukinumab, and upadacitinib.

Hidradenitis suppurativa affects 0.7 to 1.5 percent of the global population and causes substantial disability and meaningfully impairs quality of life, according to the 2026 American Academy of Dermatology guidelines.

The 2026 guidelines include 37 evidence-based recommendations for hidradenitis suppurativa management, with five medications receiving strong recommendations and 32 additional treatments receiving conditional recommendations based on available research.

The American Academy of Dermatology guidelines strongly recommend routine pain assessment as a core component of hidradenitis suppurativa treatment, recognizing pain management as essential to patient care.

The Quick Take

  • What they studied: What are the best treatments for hidradenitis suppurativa, a chronic skin condition that causes painful bumps and abscesses?
  • Who participated: This was a systematic review, meaning experts looked at all existing research studies about hidradenitis suppurativa treatments rather than testing new patients themselves.
  • Key finding: Five medications (adalimumab, bimekizumab, infliximab, secukinumab, and upadacitinib) have strong evidence showing they work well for hidradenitis suppurativa, along with regular pain management.
  • What it means for you: If you have hidradenitis suppurativa, your doctor now has clear, science-backed guidance on which treatments are most likely to help. These guidelines should lead to faster diagnosis and better treatment plans tailored to your specific needs.

The Research Details

A team of dermatology experts conducted a systematic review, which means they searched through all published scientific studies about hidradenitis suppurativa treatments and carefully evaluated the quality of evidence for each treatment option. They used a method called GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) to determine how strong the evidence was for each recommendation. This approach helps separate treatments with solid proof from those with weaker evidence. The team then created 37 specific recommendations, labeling each as either strong (meaning the evidence is very convincing) or conditional (meaning the evidence is helpful but not as definitive).

Hidradenitis suppurativa is a serious condition that causes significant pain and disability, yet many doctors weren’t sure which treatments worked best. By reviewing all available research and creating clear guidelines, doctors can now make faster, more confident treatment decisions. This approach also helps ensure that patients get treatments proven to work rather than trying random options that might not help.

This guideline is highly reliable because it comes from two major medical organizations (the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation) and was based on systematic review of existing research. The GRADE method used ensures recommendations are ranked by how strong the evidence is. However, the guidelines are limited to evidence available from published studies, so newer treatments or approaches not yet studied may not be included.

What the Results Show

The guidelines strongly recommend five medications for treating hidradenitis suppurativa: adalimumab, bimekizumab, infliximab, secukinumab, and upadacitinib. These are all biologic drugs, meaning they work by targeting specific parts of the immune system that cause inflammation. The strong recommendation means multiple high-quality studies showed these medications significantly reduce symptoms and improve quality of life for patients. Additionally, the guidelines strongly recommend that doctors regularly assess and manage pain in hidradenitis suppurativa patients, recognizing that pain control is a critical part of treatment. The guidelines also support several other treatment options with conditional recommendations, meaning they can help but the evidence is not quite as strong.

Conditional recommendations support several other treatments including topical antibiotics (clindamycin), oral antibiotics (doxycycline, tetracycline, and clindamycin combined with rifampin), topical treatments (resorcinol), and other medications like ruxolitinib and spironolactone. The guidelines also recommend specific surgical procedures for certain patients, tobacco cessation for smokers, supportive pain management strategies, and nutritional support including zinc supplementation and vitamin D repletion. These secondary treatments may help some patients, particularly those who cannot tolerate the main medications or who have milder disease.

These 2026 guidelines represent an update to previous dermatology guidance on hidradenitis suppurativa, incorporating newer research on biologic medications and recognizing the importance of comprehensive pain management. The strong emphasis on five specific biologic drugs reflects growing evidence that these medications are more effective than older antibiotic-only approaches. The inclusion of newer medications like bimekizumab and ruxolitinib shows how treatment options have expanded as research has progressed.

This systematic review is limited to evidence available from published research studies, so very new treatments not yet studied may not be included. The guidelines don’t specify exact dosages or treatment sequences, leaving some decisions to individual doctors and patients. Additionally, because hidradenitis suppurativa affects different people differently, not every recommendation will work equally well for every patient. The guidelines also cannot account for individual patient factors like cost, access to medications, or personal preferences.

The Bottom Line

If you have hidradenitis suppurativa, discuss with your dermatologist whether one of the five strongly recommended biologic medications (adalimumab, bimekizumab, infliximab, secukinumab, or upadacitinib) might be appropriate for you. Make sure your doctor regularly assesses your pain and helps manage it effectively. If you smoke, quitting can improve outcomes. Ask about topical treatments, antibiotics, or other options if biologic medications aren’t suitable. These recommendations are based on strong scientific evidence and represent the current best practices for treatment.

Anyone diagnosed with hidradenitis suppurativa should review these guidelines with their dermatologist. People with moderate to severe disease are most likely to benefit from the strongly recommended biologic medications. Those with mild disease might start with topical treatments or antibiotics. Family members and caregivers should also understand these guidelines to support treatment decisions. Healthcare providers treating hidradenitis suppurativa should use these guidelines to inform their practice.

Most biologic medications take 4 to 12 weeks to show significant improvement, though some patients notice changes sooner. Topical treatments and antibiotics may show results within 2 to 4 weeks. Pain management should begin immediately. Full benefits may take 3 to 6 months as the body responds to treatment. Individual results vary, so patience and regular follow-up with your doctor are important.

Frequently Asked Questions

What is hidradenitis suppurativa and how common is it?

Hidradenitis suppurativa is a chronic skin condition causing painful bumps, abscesses, and scarring, typically in areas where skin rubs together. It affects 0.7 to 1.5 percent of people worldwide and significantly impacts quality of life and daily functioning.

What are the best medications for hidradenitis suppurativa according to new guidelines?

The 2026 guidelines strongly recommend five biologic medications: adalimumab, bimekizumab, infliximab, secukinumab, and upadacitinib. These medications work by targeting immune system inflammation and have the strongest scientific evidence for effectiveness.

How long does it take for hidradenitis suppurativa treatment to work?

Most biologic medications take 4 to 12 weeks to show significant improvement, while topical treatments and antibiotics may work within 2 to 4 weeks. Full benefits often take 3 to 6 months as your body responds to treatment.

Yes, the guidelines recommend quitting smoking, regular pain management, specific surgical procedures for some patients, and nutritional support including zinc and vitamin D. These work best combined with medication treatments.

Should I see a dermatologist if I think I have hidradenitis suppurativa?

Yes, a dermatologist can diagnose hidradenitis suppurativa and use these new guidelines to create a personalized treatment plan. Early diagnosis and treatment lead to better outcomes and improved quality of life.

Want to Apply This Research?

  • Track daily pain levels on a scale of 1 to 10, noting which body areas are affected and what time of day pain is worst. Record which treatments you’re using and when you take them. Note any improvements or side effects within 2 to 4 week intervals.
  • Set reminders for medication doses if using biologic drugs or antibiotics. Log pain management activities like ice application, rest periods, or supportive care. Track tobacco cessation progress if applicable. Record dietary changes like zinc or vitamin D supplementation.
  • Create a monthly summary comparing pain levels, symptom severity, and treatment response. Share this data with your dermatologist at each visit. Monitor for any side effects from medications. Track quality of life improvements like increased activity or better sleep. Adjust tracking based on which treatments your doctor recommends.

These guidelines represent evidence-based recommendations from the American Academy of Dermatology and Hidradenitis Suppurativa Foundation, but individual treatment decisions should be made in consultation with a qualified dermatologist who understands your specific medical situation. Treatment effectiveness varies between individuals, and not all recommendations will be appropriate for every patient. This information is educational and should not replace professional medical advice, diagnosis, or treatment. If you have hidradenitis suppurativa or suspect you might, consult a healthcare provider for proper evaluation and personalized treatment planning.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa. , Journal of the American Academy of Dermatology (2026). PubMed 42900024 | DOI
Topics
hidradenitis suppurativa treatment biologic medications skin condition dermatology guidelines 2026 chronic skin disease management adalimumab infliximab secukinumab pain management hidradenitis antibiotic treatment skin infection quality of life skin conditions